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Introduction {#sec1}
============

Extracellular vesicles (EVs) comprise heterogeneous membrane vesicles released by virtually all cell types ([@bib15], [@bib34], [@bib52], [@bib82]). EVs are classified according to their size and subcellular origin ([@bib7], [@bib15], [@bib52], [@bib82]). Exosomes (30--150 nm) originate from late endosomal multivesicular bodies, whereas microvesicles (100--1,000 nm) and apoptotic bodies (100--5,000 nm) derive from the shedding of the plasma membrane during steady-state conditions and cell death, respectively. The study of intercellular communication mediated by EVs has become an important topic in cancer biology. Indeed, tumor-derived EVs have been implicated in various processes during tumor progression, including immunity, angiogenesis, metastasis, and resistance to anticancer therapy ([@bib3], [@bib19], [@bib36], [@bib60], [@bib70]).

Most studies have focused on the characterization of EVs isolated from cancer cells cultured *in vitro* ([@bib3], [@bib70]). Recent studies have also examined the properties of tissue-derived EVs ([@bib16], [@bib47], [@bib85], [@bib88]), including EVs isolated directly from tumors ([@bib34], [@bib76]). However, the histological complexity of tumors is such that multiple cell types---and not only cancer cells---may produce EVs whose origins, properties, and effects on the tumor microenvironment (TME) and distant organs are still largely unexplored.

In tumors, cancer cells are admixed with a number of cell types of host origin that modulate tumor progression and response to therapy ([@bib23], [@bib30]). Among immune cells, tumor-associated macrophages (TAMs) are prominent host-derived constituents of solid tumors that modulate several aspects of tumor progression, namely angiogenesis, immunosuppression, and cancer cell intravasation and metastasis ([@bib19], [@bib20], [@bib42], [@bib51]). The genetic elimination of macrophages delays tumor progression by impairing angiogenesis and metastasis ([@bib18], [@bib45]). Colony-stimulating factor-1 receptor (CSF1R) is critical for the development and survival of TAMs ([@bib62]). Accordingly, the anti-CSF1R monoclonal antibody 2G2 ([@bib66]) effectively depletes TAMs and provides therapeutic benefits in combination with antiangiogenic drugs, immune checkpoint inhibitors, and costimulatory molecule agonists ([@bib32], [@bib35], [@bib58]). Preclinical studies in mice have encouraged combining macrophage-depleting or reprogramming agents with various frontline anticancer therapies in patients with cancer ([@bib8], [@bib17], [@bib65], [@bib69]).

TAMs regulate the functions of various host cell types in the TME, including vascular cells and lymphocytes ([@bib19], [@bib51]). This regulation is known to primarily involve the production of cytokines and matrix-remodeling enzymes, but the potential participation of macrophage-derived EVs to heterotypic cell communication in tumors has been poorly studied. Owing to the lack of established procedures for isolating macrophage-derived EVs directly from tumors, most studies have investigated EVs purified from cultured macrophages ([@bib9], [@bib41], [@bib74], [@bib89], [@bib90]). Notably, TAMs exhibit a high degree of phenotypic and functional plasticity, which depends on the exact properties of the TME in which they reside ([@bib1], [@bib8], [@bib51]). In this study, we characterize the proteomic and lipidomic profiles of TAM-derived EVs, as well as their effects on cancer cells and T cells. Our results suggest that TAM-derived EVs may have functions in the TME that do not necessarily reflect the well-established properties of source TAMs.

Results {#sec2}
=======

TAM Elimination through CSF1R Blockade Enables Differential Enrichment of TAM-EVs from MC38 Colorectal Tumors {#sec2.1}
-------------------------------------------------------------------------------------------------------------

We used macrophage-rich MC38 colorectal tumors ([@bib1], [@bib32], [@bib66]) to isolate TAM-derived EVs. We inoculated MC38 cells subcutaneously in C57BL/6 mice and used the anti-CSF1R antibody 2G2 ([@bib1], [@bib32], [@bib66]) to eliminate TAMs from early established (day 4) tumors ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Two spaced doses of 2G2 slightly delayed tumor growth ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and, consistent with previous studies ([@bib1], [@bib32], [@bib66]), markedly reduced F4/80^+^ TAMs ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). Both M2-like (MRC1^+^) and M1-like (CD11c^+^ or MHCII^+^) TAMs ([@bib54], [@bib64], [@bib73]) were effectively depleted, according to immunofluorescence staining of tumor sections. Flow cytometry analysis further revealed that ablation of F4/80^+^ TAMs was associated with a modest increase of Ly6G^+^Ly6C^--^ neutrophils and granulocytic myeloid-derived suppressor cells ([@bib27]) in the CD45^+^ hematopoietic cell compartment of anti-CSF1R-treated tumors ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F).

We reasoned that comparative analysis of intact and macrophage-depleted MC38 tumors could provide a model for investigating TAM-derived EVs. MC38 tumor-bearing mice, either treated with isotype-matched immunoglobulin G (IgG) or anti-CSF1R, were transcardially perfused with PBS shortly before tumor harvesting to limit co-purification of EVs from the intratumoral circulation. To enhance recovery of tumor-derived EVs, we pooled several tumors from the same treatment group prior to non-enzymatic (mild mechanical) tissue dissociation. We then isolated EVs by using established protocols based on sequential centrifugation steps ([@bib12], [@bib36], [@bib81]). The final high-speed ultracentrifugation (110,000 × g) allows for recovery of enriched EVs, which can be processed through density gradient fractionation to further increase purity ([Figure 1](#fig1){ref-type="fig"}A). In MC38 tumors, viable tumor-derived cells accounted for about 90% and 80% of the total cells in IgG and anti-CSF1R treatment groups, respectively ([Figure 1](#fig1){ref-type="fig"}B).Figure 1EV Isolation from MC38 Tumors of IgG- and Anti-CSF1R-Treated Mice(A) Procedure to isolate EVs from IgG- and anti-CSF1R-treated tumors.(B) Flow cytometry of MC38-tumor-derived cells (day 14 post-tumor challenge; see [Figure S1](#mmc1){ref-type="supplementary-material"}A). Data show percentage values (mean ± SEM; n = 5 mice/condition). Statistics by unpaired two-tailed Student's t test.(C) Yield of EVs prior to sucrose fractionation, determined by BCA (mean ± SEM; n = 5 independent EV preparations). Statistics as in (B).(D) Representative TEM images of EVs obtained as in (C). One representative EV preparation is shown for IgG and anti-CSF1R-treated tumors. Scale bars, 200 nm.(E) EV concentration and size distribution by NTA (mean ± SEM; n = 3 acquisitions/sample). One representative EV preparation per condition is shown.(F) Correlation between EV protein content and EV concentration, determined by BCA and NTA, respectively (mean ± SD; n = 3 serial dilutions/sample). A simple linear regression function was used. One representative EV preparation per condition is shown.(G) WB analysis of cells and matched EVs from cultured MC38 cells or MC38 tumors. One representative cell or EV preparation per condition is shown.(H) EV protein content and EV concentration in each sucrose fraction, determined by BCA and NTA, respectively (mean of 2--3 technical replicates). One representative EV preparation per condition is shown.(I) EV concentration and size distribution by NTA (mean ± SEM; n = 3 acquisitions/sample). One representative EV preparation per condition is shown.(J) Yield of EVs recovered from the third top fraction of the sucrose gradient, determined by BCA (mean ± SEM; n = 5 independent EV preparations). Statistics as in (B).(K) Representative TEM images of EVs recovered from the third top sucrose fraction. One representative EV preparation per condition is shown. Scale bars, 200 nm.(L) WB analysis of EVs after sucrose gradient fractionation. Upper panel shows a representative experiment; equal sample volumes were loaded in each lane. Lower panels show relative band intensities of MRC1 and GAPDH (mean ± SEM; n = 3 independent EV preparations, one of which is shown in the WB above). For each protein, the relative signal intensity in each fraction is indicated as percentage of the total signal from all fractions.(M) Taqman analysis of selected microRNAs (normalized to miR-16-5p; fold-change versus anti-CSF1R-EVs) in EVs after sucrose gradient fractionation (mean ± SEM; n = 3 independent EV preparations). Statistics by two-way ANOVA with Sidak's multiple comparison test.Statistical significance of the data: ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

We first characterized EVs prior to sucrose density fractionation. The recovery yield was about 2 mg of EVs per gram of tumor, in both IgG and anti-CSF1R conditions ([Figure 1](#fig1){ref-type="fig"}C). Transmission electron microscopy (TEM) and nanoparticle-tracking analysis (NTA) of EVs did not reveal differences in morphology, concentration, or size distribution between EVs from IgG-treated tumors (IgG-EVs) and EVs from anti-CSF1R-treated tumors (anti-CSF1R-EVs) ([Figures 1](#fig1){ref-type="fig"}D--1F). Western blot (WB) analysis of EVs indicated enrichment of EV-associated proteins, such as ALIX and CD81, in EV preparations compared to tumor-derived cells ([Figure 1](#fig1){ref-type="fig"}G). However, these EV markers were less enriched in both IgG-EVs and anti-CSF1R-EVs compared to EVs isolated from MC38 cells cultured in a bioreactor (MC38-EVs; [Figures 1](#fig1){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}A--S2C). These differences could be due to higher heterogeneity of tumor-derived EV populations ([@bib34], [@bib52]).

To improve EV purity, we performed sucrose gradient fractionation, which allows for removing large protein aggregates and enables the separation of membrane vesicles according to density. NTA and bicinchoninic acid assay (BCA) of the recovered sucrose fractions revealed heterogeneous EV populations with densities ranging from 1.10 to 1.20 g/ml in both IgG-EVs and anti-CSF1R-EVs ([Figures 1](#fig1){ref-type="fig"}H and 1I). Notably, the majority of EVs were found in the third top (1.14 g/ml) fraction, in agreement with previous work ([@bib4], [@bib16], [@bib38]). The recovery yield after sucrose gradient fractionation was about 0.9 and 0.7 mg of EVs per gram of tumor for IgG-EVs and anti-CSF1R-EVs, respectively, indicating a loss of about 60% of starting EV material ([Figure 1](#fig1){ref-type="fig"}J). Similar to unfractionated EVs, TEM analysis of EVs from the third top fraction showed cup-shaped membrane vesicles of variable size ([Figure 1](#fig1){ref-type="fig"}K).

Post-fractionation analysis of EVs revealed enrichment of classical EV proteins (ALIX, CD63, TSG101, CD81, and CD9) in the third top fraction ([Figure 1](#fig1){ref-type="fig"}L). Expression of the macrophage-specific markers MRC1/CD206 and miR-511-3p, which are encoded by the *Mrc1* gene ([@bib73]), were markedly lower in anti-CSF1R-EVs ([Figures 1](#fig1){ref-type="fig"}L and 1M), consistent with efficient depletion of TAM-derived EVs after CSF1R blockade.

GP96, a protein associated with the endoplasmic reticulum (ER), was detected in the third top fraction. ER proteins are typically considered contaminants of EV preparations ([@bib38], [@bib81]); however, their association with secreted EVs has been recently documented ([@bib12], [@bib38], [@bib76]). To assess whether our non-enzymatic digestion protocol liberated ER vesicles in excess of other methods, we also implemented a method minimally modified from protocols previously used to purify EVs from brain tissue ([@bib85]) or tumors ([@bib76]). This protocol involved enzymatic (collagenase-based) incubation of the tissue and yielded slightly fewer and more heterogeneous EVs compared to isolation after non-enzymatic tissue dissociation, as shown by NTA ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Nevertheless, we did not observe major differences between the two methods when we examined EV- and ER-associated proteins by WB ([Figure S2](#mmc1){ref-type="supplementary-material"}E), even after immunoprecipitation (IP) of EVs with anti-CD9-coated beads ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Overall, these results indicate that tumor-derived EVs, either comprising or depleted of TAM-derived EVs, display physical properties and features of bona fide small EVs.

Comparative Proteomic Analysis of IgG-EVs and Anti-CSF1R-EVs Identifies a TAM-EV Protein Profile {#sec2.2}
------------------------------------------------------------------------------------------------

We then examined the proteome of IgG-EVs and anti-CSF1R-EVs by liquid chromatography-tandem mass spectrometry (LC-MS/MS). We selected proteins that were differentially represented in IgG-EVs and anti-CSF1R-EVs by setting a mean fold-change (FC) of \>1.7 as arbitrary threshold ([Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). We then performed Gene Ontology (GO) enrichment analysis of differentially represented EV proteins identified prior to or after sucrose gradient fractionation ([Figure 2](#fig2){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}). EV preparations prior to sucrose fractionation were enriched in RNA-associated proteins, whereas EVs recovered from the third top sucrose fraction were enriched in proteins implicated in immune responses, lipid metabolism, and vesicle trafficking. Interestingly, we did not detect RNA-related GO terms in EVs after sucrose fractionation, suggesting that proteins of the RNA machinery are likely contaminants of EV preparations, consistent with recent work ([@bib34]). These observations motivated us to focus subsequent studies on tumor-EVs obtained by sequential centrifugation followed by density fractionation.Figure 2Enrichment and Interactome Analysis of EV Proteins(A) LC-MS/MS-based GO enrichment analysis, prior to and after sucrose gradient fractionation, of MC38 EV-associated proteins, whose fold-change (FC) abundance was \> 1.7 in IgG-EVs versus anti-CSF1R-EVs. Data were generated from 2 independent EV preparations.(B and C) LC-MS/MS-based immune cell enrichment (B) and interactome (C) analysis of MC38 EV-associated proteins (IgG versus anti-CSF1R, FC \> 1.7) obtained after sucrose gradient fractionation. Data were generated from 4 independent EV preparations. Three proteins (LRRC25, CYP4F3, and CD300LD4) were not detected in the Immuno-Navigator database.

An analysis of four independent tumor-derived EV preparations produced a list of 81 proteins (*TAM-EV* proteins) consistently decreased after anti-CSF1R treatment (IgG versus CSF1R, FC \>1.7; [Table S2](#mmc3){ref-type="supplementary-material"}). We then implemented the 81-protein profile to enrichment analysis with Immuno-Navigator, a database for gene co-expression in cells of the immune system ([@bib83]). As expected, many proteins matched to genes highly expressed in macrophages, dendritic cells, and monocytes ([Figure 2](#fig2){ref-type="fig"}B). The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING)-based protein association analysis predicted multiple interactions ([Figure 2](#fig2){ref-type="fig"}C) among proteins involved in macrophage biology, Toll-like receptor (TLR) signaling, complement cascade, lipid metabolism, signal transduction, cell adhesion, and immune response and inflammation ([Figures 3](#fig3){ref-type="fig"}A--3G). We confirmed by WB analysis the enrichment of MRC1 and TMEM173, also known as stimulator of interferon genes (STING), in IgG-EVs compared to both tumor-derived cells and anti-CSF1R-EVs ([Figure 3](#fig3){ref-type="fig"}H). We obtained similar results when we applied an enzymatic incubation-based protocol ([@bib76], [@bib85]) to isolate EVs ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H).Figure 3Proteomic Analysis of IgG-EVs and Anti-CSF1R-EVs and Comparison with BMM-EVs and MC38-EVs(A--G) LC-MS/MS and classification of TAM-EV proteins (criteria: IgG versus anti-CSF1R FC \> 1.7) according to their associated pathways. Data show normalized quantitative values (mean ± SEM; n = 4 independent EV preparations). Statistics by two-way ANOVA with Holm-Sidak's multiple comparison test.(H) WB analysis of cells and EVs from tumors, MC38 cells, and M2 macrophages (BMM). One representative EV preparation per condition is shown.(I) Schematic of EV isolation (left) and Venn diagram (right) comparing proteins detected by LC-MS/MS in MC38-EVs (3 independent EV preparations) and M1 and M2 BMM-EVs (2 independent EV preparations).(J) Classical macrophage markers in M1 and M2 BMM-EVs. Data show mean quantitative values normalized to ALIX (2 independent EV preparations).(K and L) Venn diagrams comparing proteins enriched in IgG-EVs versus anti-CSF1R-EVs (FC \> 1.7; K) or anti-CSF1R-EVs versus IgG-EVs (FC \> 1.7; L) with those detected in MC38-EVs and M1 and M2 BMM-EVs.(M) MC38-tumor-derived EV proteins of likely neutrophil origin (anti-CSF1R/IgG FC \> 1.7). Data show normalized quantitative values (mean ± SEM; n = 4 independent EV preparations). Statistics as in (A).

We next asked if our comparative approach accurately identified macrophage-specific proteins. To this aim, we performed LC-MS/MS protein analysis of MC38-EVs and EVs isolated from cultured M1- or M2-polarized bone marrow macrophages (BMM-EVs) obtained after stimulation with interferon-gamma (IFNγ) plus lipopolysaccharide (LPS) or interleukin-4 (IL-4), respectively ([Figures 3](#fig3){ref-type="fig"}I and 3J; [Table S3](#mmc4){ref-type="supplementary-material"}). Although many proteins were shared by all EV preparations, only 5 (∼6%) of the 81 TAM-EV proteins were detected in MC38-EVs, whereas 36 (∼44%) were also detected in BMM-EVs ([Figure 3](#fig3){ref-type="fig"}K). Moreover, we selected EV proteins increased in anti-CSF1R-EVs (i.e., after TAM elimination; FC \>1.7; [Table S3](#mmc4){ref-type="supplementary-material"}) and analyzed their degree of similarity with proteins detected in MC38-EVs and BMM-EVs. Out of the 68 proteins enriched in anti-CSF1R-EVs, 41 (∼60%) were also detected in MC38-EVs, whereas only 12 (∼18%) were detected in BMM-EVs, 9 of which were also present in MC38-EVs ([Figure 3](#fig3){ref-type="fig"}L). Of note, some of the enriched proteins were typical neutrophil-associated proteins ([Figure 3](#fig3){ref-type="fig"}M), consistent with the relative increase of neutrophils in TAM-depleted tumors (see [Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F).

In summary, the aforementioned data indicate that EV-associated proteins that decrease after anti-CSF1R treatment of MC38 tumors are strongly indicative of TAM-EV-associated proteins. Conversely, proteins that increase in tumor-derived EVs after anti-CSF1R are, at least partly, indicative of proteins associated with cancer cell- and neutrophil-derived EVs.

Macrophages and Cancer Cells Are the Main Cellular Sources of EVs in MC38 Tumors {#sec2.3}
--------------------------------------------------------------------------------

We then sought to determine the relative contribution of distinct cell types to EVs in MC38 tumors. In LysM.Cre/ROSA^mT/mG^ transgenic mice ([@bib13], [@bib56]), the ROSA^mT/mG^ locus directs ubiquitous expression of tdTomato, which switches to GFP expression in myeloid cells that express the Cre recombinase under the LysM promoter. Owing to their membrane-targeted localization, tdTomato and GFP may be transferred to EVs, thus allowing for tracing EVs of different cellular origin.

Confocal imaging and flow cytometry analysis indicated that that 99% of CD11b^+^F4/80^+^ BMMs derived from LysM.Cre/ROSA^mT/mG^ mice were indeed GFP^+^ ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). A small fraction of the cells (∼8%) were GFP/tdTomato double positive, possibly due to recent Cre recombination and incomplete fluorescence switch, whereas less than 1% were tdTomato single positive, hence of non-myeloid origin. As expected, we did not detect GFP in BMMs of wild-type and control ROSA^mT/mG^ mice. Immunofluorescence analysis of the cells confirmed membrane localization of GFP, in particular, at the plasma membrane and in RAB7^+^ late endosomes ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

We characterized EVs purified from BMMs of LysM.Cre/ROSA^mT/mG^ and ROSA^mT/mG^ mice by WB, NTA, and TEM ([Figures S3](#mmc1){ref-type="supplementary-material"}D--S3F). GFP was detected in BMM-EVs of LysM.Cre/ROSA^mT/mG^ mice, whereas it was barely detectable in BMM-EVs of control ROSA^mT/mG^ mice and absent in MC38-EVs, according to WB analysis. We also confirmed green and red fluorescence of BMM-EVs of LysM.Cre/ROSA^mT/mG^ and ROSA^mT/mG^ mice, respectively, by flow cytometry ([Figure S3](#mmc1){ref-type="supplementary-material"}G).

We then inoculated MC38 cancer cells in LysM.Cre/ROSA^mT/mG^ mice, which were treated as shown in [Figure S1](#mmc1){ref-type="supplementary-material"}A above. In that setting, tumor-associated cells were fluorescent as follows: myeloid cells (mostly TAMs in the IgG condition) were largely GFP^+^/tdTomato^--^ and partly GFP^+^/tdTomato^+^; non-myeloid host cells were GFP^--^/tdTomato^+^; and MC38 cancer cells were GFP^--^/tdTomato^--^ ([Figures 4](#fig4){ref-type="fig"}A, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B). Next, we collected tumor-derived EVs ([Figure 4](#fig4){ref-type="fig"}A) and immunoprecipitated them with anti-CD9-coated magnetic beads. Notably, WB analysis revealed GFP in CD9^+^ IgG-EVs but much less so in CD9^+^ anti-CSF1R-EVs, confirming marked depletion of TAM-EVs after anti-CSF1R treatment. In line with results shown above, IP of MC38-EVs, IgG-EVs, and anti-CSF1R-EVs by anti-CD9-coated beads enriched both CD81 and the ER protein calnexin (CANX; [Figure 4](#fig4){ref-type="fig"}B).Figure 4Quantification of TAM-EVs and Validation of the TAM-EV Protein Signature by IP of CD11b^+^ Tumor-Derived EVs(A) Procedure to isolate EVs from MC38 tumors grown in LysM.Cre/ROSA^mT/mG^ mice.(B) WB analysis of EVs isolated from cultured MC38 cells or MC38 tumors grown in LysM.Cre/ROSA^mT/mG^ mice, after IP with anti-CD9 or control-coated magnetic beads. One representative EV preparation per condition is shown.(C and D) Flow cytometry analysis of tumor-EVs isolated from wild-type (WT) or LysM.Cre/ROSA^mT/mG^ mice. Data show representative dot plots of GFP and tdTomato (C) and quantitative values (mean ± SD; n = 3 independent experiments; D). Statistics by two-way ANOVA, using Sidak's multiple comparison test.(E) LC-MS/MS analysis of EVs showing quantitative values (mean ± SEM; n = 4 or 3 independent preparations) for CD11b, ALIX, and CD81, normalized to CD9. Statistics by two-way ANOVA, using Tukey's multiple comparison test.(F) IP procedure for capturing CD11b^+^ EVs.(G) Flow cytometry analysis of PKH67-labeled EVs bound to anti-CD9, anti-CD11b or isotype-control beads. Data show percentage values (mean ± SEM; n = 4 and 5 preparations for CD11b and CD9 IP, respectively).(H) WB analysis of tumor-derived EVs after IP. One representative EV preparation per condition is shown.(I) Venn diagrams comparing proteins enriched in IgG-EVs versus anti-CSF1R-EVs (FC \> 1.7; see [Table S2](#mmc3){ref-type="supplementary-material"}) with those detected in CD11b^+^ IgG-EVs after IP (FC versus isotype control beads \> 2; see [Table S4](#mmc5){ref-type="supplementary-material"}). IP was performed on the same IgG-EV preparation shown in (H).(J) Radial table reporting the 62 proteins of the MC38 TAM-EV signature and their association with biological pathways. The graphical representation limits connection of each protein to two pathways (see also [Table S5](#mmc6){ref-type="supplementary-material"}).(K) The data in (I) are shown after removing potential protein contaminants identified according to the CRAPome database.See also [Figures S3](#mmc1){ref-type="supplementary-material"}, [S4](#mmc1){ref-type="supplementary-material"}, [S5](#mmc1){ref-type="supplementary-material"}, and [S6](#mmc1){ref-type="supplementary-material"}.

To quantitate tumor-derived EVs of different cellular origin, we labeled them with the lipophilic fluorescent dye DiR before flow cytometry to distinguish them from background noise ([Figures 4](#fig4){ref-type="fig"}C, 4D, [S4](#mmc1){ref-type="supplementary-material"}C, and S4D). GFP^+^/tdTomato^--^ EVs (mostly deriving from TAMs) were the majority (average 57%) of IgG-EVs and the minority (average 18%) of anti-CSF1R-EVs ([Figures 4](#fig4){ref-type="fig"}C and 4D), consistent with TAM depletion. Cancer-cell-derived GFP^--^/tdTomato^--^ EVs, which represented 29% of the total IgG-EVs, increased up to 64% in anti-CSF1R-EVs. GFP^+^/tdTomato^+^ and GFP^--^/tdTomato^+^ EVs were scarce in both IgG-EVs and anti-CSF1R-EVs, and their proportions did not significantly change after TAM depletion. Overall, these data indicate that TAMs and cancer cells are the main sources of EVs in IgG- and anti-CSF1R-treated MC38 tumors, respectively, consistent with the EV-associated protein profiles shown in [Figure 3](#fig3){ref-type="fig"} above.

Lastly, we performed LC-MS/MS of GFP^+^/tdTomato^--^ and GFP^--^/tdTomato^--^ IgG-EVs isolated by fluorescence-activated cell sorting (FACS). Due to the limited amounts of GFP^+^ EVs recovered after sorting, we were only able to detect the most abundant proteins in the TAM-EV profile ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Nevertheless, all measurable TAM-EV proteins, as well as GFP, were either absent or exceedingly scarce in GFP^--^/tdTomato^--^ EVs.

Immunoisolation and Analysis of CD11b^+^ EVs Corroborate a TAM-EV Protein Signature {#sec2.4}
-----------------------------------------------------------------------------------

The differential proteomic analysis of IgG-EVs and anti-CSF1R-EVs shown above could not rule out proteins associated with EVs from cellular sources other than TAMs, for example, cell types whose abundance and biology in tumors are indirectly altered by macrophage depletion ([@bib8]). Thus, we sought to validate the TAM-EV protein profile with a second approach. We used anti-CD11b-coated magnetic beads to immunoprecipitate CD11b^+^ EVs from MC38-tumor-derived EVs ([Figure 4](#fig4){ref-type="fig"}E). This procedure ([Figure 4](#fig4){ref-type="fig"}F) enriched EVs secreted by CD11b^+^ myeloid cells ([Figures 4](#fig4){ref-type="fig"}G and 4H; [Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C), of which macrophages and monocytes constitute the vast majority (\> 90%) in IgG-treated tumors (see [Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F above). The IP was specific, as neither MC38-EVs ([Figure 4](#fig4){ref-type="fig"}G) nor HER2^+^-cancer-cell-derived EVs isolated from HER2^+^ MC38 tumors ([Figures S5](#mmc1){ref-type="supplementary-material"}D, S5E and S5F) grown in human HER2-tolerant Wap-*ERBB2* mice ([@bib61]) did bind to anti-CD11b-coated beads. LC-MS/MS analysis showed that, of the 81 proteins in the TAM-EV profile determined by the comparative analysis of IgG-EVs and anti-CSF1R-EVs, 62 were also enriched in CD11b^+^ IgG-EVs (FC versus control beads, \>2; [Figures 4](#fig4){ref-type="fig"}H--4J; [Table S4](#mmc5){ref-type="supplementary-material"}). Importantly, the number of shared proteins was not altered by the removal of potential IP contaminants ([Figure 4](#fig4){ref-type="fig"}K) identified in the Contaminant Repository for Affinity Purification of Mass Spectrometry Data (CRAPome) database ([@bib53]).

In summary, two complementary strategies identified a 62-protein signature for TAM-EVs of MC38 tumors, which encompasses proteins involved in immune response and inflammation but also lipid transport and metabolism, cell adhesion, migration, and signal transduction ([Figure 4](#fig4){ref-type="fig"}J; [Table S5](#mmc6){ref-type="supplementary-material"}). Notably, the contribution of non-macrophage, myeloid-derived EVs to the TAM-EV protein signature was arguably negligible, as IgG-treated MC38 tumors contained scarce granulocytic infiltrates.

TAM-EVs Display an M1-like TAM Signature and Promote T Cell Proliferation and Activation {#sec2.5}
----------------------------------------------------------------------------------------

As shown above, CD11b^+^ cells of MC38 tumors are mostly macrophages or monocytes ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F). To compare the TAM-EV protein signature with that of source cells (TAM-Cells), we performed LC-MS/MS of CD11b^+^ cells isolated by FACS from IgG- and anti-CSF1R-treated MC38 tumors ([Figure S6](#mmc1){ref-type="supplementary-material"}A; [Table S6](#mmc7){ref-type="supplementary-material"}). Of the consolidated 62-protein TAM-EV signature, 37 were also enriched in TAM-Cells of IgG-treated tumors (versus anti-CSF1R; FC \> 1.7), indicating partial overlap between the profiles of TAM-Cells and TAM-EVs ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Similar to TAM-EVs, GO enrichment analysis of TAM-Cells identified processes involved in immune regulation ([Figure S6](#mmc1){ref-type="supplementary-material"}C; [Table S6](#mmc7){ref-type="supplementary-material"}). However, contrary to TAM-EVs, we did not identify lipid metabolism among the top 20 GO terms, suggesting a potential enrichment of lipid metabolism-associated proteins in EVs compared to source TAMs.

We then used previously described gene expression data of FACS-sorted murine M1-like and M2-like TAMs ([@bib73]) to ask whether protein signatures of TAM-Cells and TAM-EVs reflected an M1-like or M2-like profile. Interestingly, although TAM-Cells bore resemblance to an M2-like phenotype, the TAM-EV signature better represented an M1-like phenotype ([Figure 5](#fig5){ref-type="fig"}A).Figure 5Immunomodulatory Profile and Functions of TAM-EVs(A and B) Gene set enrichment analysis (GSEA) plots showing the correlation of TAM (TAM-Cell) and TAM-EV protein signatures with genes expressed in FACS-sorted M1-like or M2-like TAMs (A) or prognostic genes across human cancers recorded in the PRECOG database (B).(C) Flow cytometry analysis of CD8^+^ T cells obtained after priming OT-I splenocytes.(D) Schematic of the experiment shown in (E--G).(E and F) Flow cytometry analysis of CD8^+^ OT-I proliferation assessed by CellTrace dilution.(E) Representative flow profiles.(F) Quantification of the data (mean ± SEM; n = 4 cell cultures/condition). Statistics by two-way ANOVA, using Sidak's multiple comparison test.(G) ELISA-based quantification of IFNγ in medium conditioned by OT-I CD8^+^ T cells. Data are shown as mean ± SEM (n = 4 cell cultures/condition). Statistics as in (F).(H) Flow cytometry analysis of CD8^+^ T cells purified from the spleen of C57BL/6 mice.(I) Schematic of the experiment shown in (J and K).(J) Flow cytometry analysis of CD8^+^ T cell proliferation assessed by CellTrace dilution (mean ± SEM; n = 4 cell cultures/condition). Statistics by one-way ANOVA, using Tukey's multiple comparison test.(K) ELISA-based quantification of IFNγ in medium conditioned by CD8^+^ T cells (mean ± SEM; n = 4 cell cultures/condition). Statistics as in (J).(L) Flow cytometry analysis of CD4^+^ T cells purified from the spleen of BALB/c mice.(M) Schematic of the experiment shown in (N).(N) Flow cytometry analysis of CD4^+^ T cell proliferation assessed by CellTrace dilution (mean ± SEM; n = 4 cell cultures/condition). Statistics as in (J).(O) Schematic of the experiment shown in (P).(P) Flow cytometry analysis of activation markers (mean fluorescence intensity, MFI) in CD11b^+^CD11c^+^ BMDCs (mean ± SEM; n = 4 cell cultures/condition). Statistics by two-way ANOVA, using Dunnett's multiple comparison test (each treatment condition versus control DMSO).

Because M1 and M2 TAM phenotypes correlate with anti- and pro-tumoral properties, respectively ([@bib1], [@bib8], [@bib51]), we asked whether the signatures of TAM-Cells and TAM-EVs could associate with differential clinical outcome in patients with cancer by using the Prediction of Clinical Outcomes from Genomics (PRECOG) database ([@bib29]). Interestingly, although the TAM-Cell signature correlated neither with a good nor bad clinical outcome, the TAM-EV signature strongly correlated with improved survival ([Figure 5](#fig5){ref-type="fig"}B).

M1-like TAMs may have T cell stimulatory activity in tumors ([@bib1], [@bib8], [@bib51]). Because TAM-EVs display an M1-like signature, we hypothesized that they could stimulate CD8^+^ T cell proliferation and activation. To this aim, we generated antigen-specific CD8^+^ T cells from transgenic OT-I mice, whose T cell receptor specifically recognizes the ovalbumin (OVA) peptide SIINFEKL loaded on MHC-I/H-2kB ([@bib31]). We primed splenic OT-I cells with SIINFEKL for 1 h and expanded CD8^+^ T cells in the presence of IL-2 for 4 days ([Figure 5](#fig5){ref-type="fig"}C). We then exposed them to IgG-EVs or anti-CSF1R-EVs for 24 h ([Figure 5](#fig5){ref-type="fig"}D) and examined CD8^+^ T cell proliferation by using the CellTrace Violet tracer ([Figure 5](#fig5){ref-type="fig"}E). Notably, whereas anti-CSF1R-EVs did not affect cell proliferation, IgG-EVs significantly enhanced it, suggesting a TAM-EV-dependent effect ([Figures 5](#fig5){ref-type="fig"}E and 5F). Furthermore, the presence of TAM-EVs both accelerated and enhanced IFNγ secretion by CD8^+^ T cells, as shown by comparing results obtained at 24 h and 48 h ([Figure 5](#fig5){ref-type="fig"}G). To validate these results in another model, we used CD8^+^ T cells isolated from non-transgenic C57BL/6 mice ([Figure 5](#fig5){ref-type="fig"}H); in these experiments, naive CD8^+^ T cells were concomitantly primed with anti-CD3/CD28 beads and incubated with EVs ([Figure 5](#fig5){ref-type="fig"}I). As seen with OT-I cells, TAM-EV-containing IgG-EVs enhanced both the proliferation and IFNγ secretion by activated T cells ([Figure 5](#fig5){ref-type="fig"}J and 5K). Finally, we examined whether TAM-EVs could support CD4^+^ T cell proliferation in an allogenic assay involving incubation of CD4^+^ T cells of BALB/c origin ([Figure 5](#fig5){ref-type="fig"}L) with EVs of C57BL/6 origin ([Figure 5](#fig5){ref-type="fig"}M). Only IgG-EVs promoted CD4^+^ T cell proliferation ([Figure 5](#fig5){ref-type="fig"}N), again suggesting the requirement of TAM-EVs for T cell activation and proliferation. Of note, both IgG-EVs and anti-CSF1R-EVs had negligible effects on the expression of activation markers of bone-marrow-derived dendritic cells (BMDCs), such as CD80, CD86, MHC-II, and CD40 ([Figures 5](#fig5){ref-type="fig"}O and 5P). Together, these data argue that TAM-EVs may have direct T-cell-stimulatory capacity.

TAM-EVs Carry the Biosynthetic Machinery for Thromboxane Production {#sec2.6}
-------------------------------------------------------------------

Several proteins in the TAM-EV signature (see [Figure 4](#fig4){ref-type="fig"}J above) are involved in lipid metabolism. In particular, CYP4F3, TBXAS1, COX1, and CYP4F16 participate in the biosynthesis of lipid metabolites derived from arachidonic acid (AA), such as prostaglandins (PGs), leukotrienes (LTs), and thromboxanes (TXs). These lipids, broadly referred to as eicosanoids, are signaling molecules of exceptional importance during inflammation and its resolution and have been extensively studied in the context of cancer ([@bib14], [@bib43], [@bib87]). Eicosanoids are produced by both cancer cells and tumor-associated cells, including macrophages, and appear to possess both pro- and anti-tumoral properties ([@bib14]). It was recently reported that the origin of eicosanoids might also involve transcellular mechanisms ([@bib14], [@bib26]), implicating EVs as carriers of these lipids or the enzymes involved in their biosynthesis ([@bib5], [@bib24], [@bib48], [@bib49], [@bib50], [@bib71], [@bib78]). Therefore, we sought to examine lipids and enzymes of the AA pathway in tumor-derived EVs.

LC-MS/MS proteome analysis of IgG-EVs, anti-CSF1R-Evs, and MC38-EVs (see [Tables S2](#mmc3){ref-type="supplementary-material"} and [S3](#mmc4){ref-type="supplementary-material"} above) pinpointed enzymes involved in the three main branches of AA metabolism ([Figure 6](#fig6){ref-type="fig"}A): (1) cyclooxygenase (COX) pathway, which produces PGs and TXs; (2) lipoxygenase (LOX) pathway, involved in the biosynthesis of LTs and hydroxyeicosatetraenoic acids (HETEs); and (3) cytochrome P450 epoxygenase (CYP) pathway, which catalyzes the biosynthesis of diverse lipid intermediates, including epoxygenated fatty acids (EETs) ([@bib87]). The phospholipase A~2~ (PLA~2~), which releases AA from phospholipids, was detected at low levels in the three EV populations ([Figure 6](#fig6){ref-type="fig"}B). Both COX1 and TX A synthase 1 (TBXAS1) were strongly enriched in TAM-EVs (based on their differential representation in IgG-EVs versus anti-CSF1R-EVs) and virtually undetectable in MC38-EVs. Conversely, COX2 and PG E synthases (PTGES2 and PTGES3) were not enriched in TAM-EVs and were detectable in MC38-EVs, suggesting preferential loading into cancer-cell-derived EVs. With the exception of CYP1B1, enzymes of the CYP pathway were mostly associated with TAM-EVs. Enzymes of the LOX pathway, especially leukotriene-A4 hydrolase (LTA4H), were abundant in MC38-EVs and were not enriched in TAM-EVs. Glutathione-S-transferases (GSTO1, GSTO1, and GSTM1), which are common to both LOX and COX pathways, also appeared enriched in cancer-cell-derived EVs. We confirmed enrichment of TBXAS1 and COX1 in IgG-EVs compared to anti-CSF1R-EVs or source cells by WB analysis ([Figure 6](#fig6){ref-type="fig"}C).Figure 6Molecular and Functional Lipidomic Profile of TAM-EVs(A) Schematic illustrating AA metabolism.(B) LC-MS/MS proteome analysis of EVs showing enzymes involved in eicosanoid synthesis. Data show quantitative values (mean ± SEM; n = 4 and 3 independent preparations of MC38-tumor-derived EVs and MC38-EVs, respectively). Statistics by two-way ANOVA, using Tukey's multiple comparison test.(C) WB analysis of cells and EVs from cultured MC38 cells or MC38 tumors. One representative EV preparation per condition is shown.(D) AA concentration (mean ± SEM; n = 4 independent EV preparations) determined by LC-MS/MS-based absolute quantification using calibration curves of internal standards. Statistics by unpaired two-tailed Student's t test.(E) TXB~2~ concentration (mean ± SEM; n = 4 independent EV preparations) determined by LC-MS/MS-based relative quantification of ion counts. Statistics as in (D).(F) Schematic illustrating putative thromboxane synthesis in TAM-EVs.(G) Quantification of eicosanoids, mostly PGs (left) and their precursor AA (right), in MC38 tumors (mean ± SEM; n = 6 mice/condition) by LC-MS/MS lipidomics. Statistics by two-way ANOVA, using Sidak's multiple comparison test (left) or unpaired two-tailed Student's t test (right).(H) CD8^+^ T cell proliferation in response to PGE~2~ or PGF~2α~; the left panel shows the experimental design. The right panel shows flow cytometry analysis of CD8^+^ T cell proliferation assessed by CellTrace dilution (mean ± SD; n = 3 cell cultures/condition). Statistics by one-way ANOVA, using Dunnett's multiple comparison test (each PG concentration versus control DMSO).(I) Confocal analysis of MC38 cells incubated with PKH67-labeled MC38 IgG-EVs (green). Nuclei are stained with 4′,6-diamidino-2-phenylindole (DAPI; blue). The merged panel is shown on the left. One representative experiment is shown. Scale bar, 10 μm.(J) WB analysis of MC38 cells incubated with EVs isolated from LysM.Cre/ROSA^mT/mG^ mice. One representative EV preparation per condition is shown.(K) Schematic of the experiment shown in (L--N).(L and M) Quantification of PUFAs (L) and eicosanoids (M) in medium conditioned by MC38 cells (mean ± SEM; n = 4 cell cultures/condition) by LC-MS/MS. Statistics as in (B).(N) ELISA-based quantification of PGE~2~ and TXB~2~ (mean ± SEM; n = 4 cell cultures/condition) in medium conditioned by MC38 cells. Statistics by one-way ANOVA, using Tukey's multiple comparison test.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

We then performed lipid profiling by reversed-phase liquid chromatography coupled to high-resolution mass spectrometry (RPLC-HRMS) of four independent preparations of IgG-EVs and anti-CSF1R-EVs isolated from MC38 tumors. Complex lipids (e.g., glycerophospholipids, glycerolipids, sphingolipids, and fatty acyls) were not differentially represented in IgG-EVs and anti-CSF1R-EVs ([Figure S7](#mmc1){ref-type="supplementary-material"}A). In addition, IgG-EVs and anti-CSF1R-EVs did not differ in their content of eicosanoid precursors, including AA ([Figure 6](#fig6){ref-type="fig"}D) and other polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ([Figure S7](#mmc1){ref-type="supplementary-material"}B) ([@bib21]). Also, we did not detect differences in the content of eicosanoids ([Figure S7](#mmc1){ref-type="supplementary-material"}C), with the exception of TX B~2~ (TXB~2~), an inactive metabolite of TX A2 (TXA~2~), which was identified only in IgG-EVs ([Figure 6](#fig6){ref-type="fig"}E). TXA~2~ is produced by TBXAS1 and, owing to its low chemical stability, is typically monitored by assessing its metabolite TXB~2~ ([@bib14]).

In summary, proteomic and lipidomic analysis of TAM-EVs showed enrichment of precursor AA, COX1 and TBXAS1 enzymes, and final product TXB~2~, suggesting that TAM-derived EVs carry the biochemical machinery required for the synthesis of TXs ([Figure 6](#fig6){ref-type="fig"}F).

TAM-EVs Alter PG and TX Production by Cancer Cells {#sec2.7}
--------------------------------------------------

The aforementioned results prompted us to question whether TAM elimination may influence eicosanoid production in the TME. We performed lipidomic analysis of whole MC38 tumors after IgG or anti-CSF1R treatment. Several PGs and their metabolites (including PGF~2α~, PGE~1~, and PGE~2~), which are synthesized by COX enzymes, namely COX2 and PGESs ([@bib87]), increased significantly in TAM-depleted tumors ([Figure 6](#fig6){ref-type="fig"}G). Importantly, macrophage depletion did not affect the relative abundance of eicosanoids produced through COX-independent pathways, such as 8,9-DiHETrE and 9-KODE, as well as the concentration of the common precursor AA. Some PGs that increased in TAM-depleted MC38 tumors, such as PGE~2~ and PGF~2α~, possess protumoral and immunosuppressive properties ([@bib87]), as also shown by their capacity to suppress CD8^+^ T cell activation *in vitro* ([Figure 6](#fig6){ref-type="fig"}H).

We then asked if TAM-EVs could alter lipid metabolism in recipient cancer cells. To this aim, we performed functional assays with cultured MC38 cells exposed to IgG-EVs or anti-CSF1R-EVs. MC38 cells internalized both IgG-EVs and anti-CSF1R-EVs ([Figures 6](#fig6){ref-type="fig"}I, 6J, and [S7](#mmc1){ref-type="supplementary-material"}D) without activating apoptotic pathways ([Figure S7](#mmc1){ref-type="supplementary-material"}E). Twenty-four h after exposure to PBS, IgG-Evs, or anti-CSF1R-EVs, MC38 cells were washed and stimulated with a calcium ionophore. We then analyzed the conditioned media with LC-MS/MS targeted to eicosanoids and their precursors, PUFAs ([Figures 6](#fig6){ref-type="fig"}K--6M). Although we did not observe significant differences in the release of PUFAs, the levels of some PGs, including the PGF~2α~, dropped in media conditioned by MC38 cells pre-treated with IgG-EVs. We did not observe effects on 11-HETE and 9-KODE, which are produced through COX-independent pathways. Because these mass spectrometry (MS)-based analyses neither discriminated between PGE~2~ and PGD~2~ nor detected TXs, we processed conditioned media by ELISA of PGE~2~ and TXB~2~. Both IgG-EVs and anti-CSF1R-EVs enhanced the release of PGE~2~ and TXB~2~ from MC38 cells ([Figure 6](#fig6){ref-type="fig"}N). However, IgG-EVs stimulated MC38 to produce higher TXB~2~ and lower PGE~2~ amounts compared to anti-CSF1R-EVs, suggesting that TAM-EVs enhance the COX1/TBXAS1 while inhibiting the COX2/PGES-dependent pathway in cancer cells.

TAM-EVs Isolated from E0771 Mammary Tumors Contain PG and TX Biosynthetic Enzymes {#sec2.8}
---------------------------------------------------------------------------------

To corroborate our results, we also examined IgG-EVs and anti-CSF1R-EVs obtained from the E0771 mammary tumor model. We injected E0771 cells subcutaneously in C57BL/6 mice and treated early established tumors with three doses of control IgG or anti-CSF1R (2G2) antibody ([Figure 7](#fig7){ref-type="fig"}A). Tumors were then harvested and processed individually.Figure 7Molecular and Functional Analysis of E0771 TAM-EVs(A) Schedule of subcutaneous E0771 cancer cell inoculation in C57BL/6 mice and drug administration.(B) Flow cytometry analysis of immune infiltrates in E0771 tumors. Data show percentage values (mean ± SD; n = 3 mice/condition). Statistics by unpaired two-tailed Student's t test (left and middle) or two-way ANOVA, using Sidak's multiple comparison test (right).(C) Yield of EVs recovered from E0771 tumors prior to and after sucrose gradient fractionation, determined by BCA (mean ± SD; n = 3 EV preparations/condition). Statistics by unpaired two-tailed Student's t test.(D) EV concentration and size distribution by NTA in the 6 sucrose fractions (mean ± SEM; n = 3 EV preparations/condition).(E) EV protein content and EV concentration in each sucrose fraction determined by BCA and NTA, respectively (mean ± SD; n = 3 EV preparations/condition).(F) Representative TEM images of EVs. One representative EV preparation per condition is shown. Scale bars, 200 nm.(G) WB analysis of cultured E0771 cells and matched EVs. One representative EV preparation is shown.(H and I) WB analysis of E0771 tumor-EVs (H). Relative signal quantification of MRC1, COX1, and TBXAS1 is shown in (I) as mean band intensity normalized to CD9 (n = 3 EV preparations/condition). Statistics as in (C).(J) Venn diagrams comparing proteins enriched in IgG-EVs versus anti-CSF1R-EVs from E0771 tumors (FC \> 1.7; see [Table S7](#mmc8){ref-type="supplementary-material"}) with those of the MC38 TAM-EV signature (see [Table S5](#mmc6){ref-type="supplementary-material"}).(K) LC-MS/MS analysis of TBXAS1 in E0771 tumor-EVs (mean ± SD; n = 3 EV preparations/condition). Statistics as in (C).(L) ELISA-based quantification of TXB~2~ in medium conditioned by E0771 cells (mean ± SD; n = 3 EV preparations/condition). Statistics by one-way ANOVA, using Tukey's multiple comparison test.

Macrophages accounted for about 40%--50% of all myeloid cells in E0771 tumors ([Figure 7](#fig7){ref-type="fig"}B). Flow cytometry analysis demonstrated marked reductions of TAMs and compensatory expansion of monocytes in anti-CSF1R-treated tumors, whereas neutrophil numbers remained low irrespective of treatment ([Figure 7](#fig7){ref-type="fig"}B). We then isolated tumor-derived IgG-EVs and anti-CSF1R-EVs, as described for MC38 tumors above, and analyzed them by BCA, NTA, and TEM ([Figures 7](#fig7){ref-type="fig"}C--7F). Because E0771 cells lack CD81 expression ([@bib86]; [Figure 7](#fig7){ref-type="fig"}G), we performed quantitative WB analysis of proteins of interest in E0771 tumor-EVs by normalizing expression to CD9 ([Figures 7](#fig7){ref-type="fig"}H and 7I). MRC1 and both COX1 and TBXAS1 were lower in anti-CSF1R-EVs compared to IgG-EVs, consistent with data obtained in MC38 tumors.

We then performed LC-MS/MS of E0771 tumor-EVs ([Table S7](#mmc8){ref-type="supplementary-material"}). Notably, 24 proteins in the 62-protein MC38 TAM-EV signature (see [Figures 4](#fig4){ref-type="fig"}I--4K above) were also enriched in IgG-EVs versus anti-CSF1R-EVs (FC \> 1.7) of E0771 tumor-EVs ([Figure 7](#fig7){ref-type="fig"}J). These included TBXAS1, which was significantly depleted in anti-CSF1R-EVs ([Figure 7](#fig7){ref-type="fig"}K).

Lastly, we exposed E0771 cancer cells to E0771-tumor-derived IgG-EVs and anti-CSF1R-EVs and, 24 h later, measured PGE~2~ and TXB~2~ release in the conditioned media by ELISA ([Figure 7](#fig7){ref-type="fig"}L). Whereas PGE~2~ was below the detection limit of the assay in all conditions, IgG-EVs and to a lesser extent anti-CSF1R-EVs increased TXB~2~ production by cancer cells. Taken together, these results confirm key findings in MC38-tumor-derived TAM-EVs and support the notion that TAM-derived EVs may stimulate TX production by recipient cancer cells in the TME.

Discussion {#sec3}
==========

Although many studies have demonstrated EV-mediated transfer of biological molecules to recipient cells ([@bib38], [@bib50], [@bib74], [@bib82]), attention has been drawn recently on the implications of EV heterogeneity ([@bib4], [@bib52]). Indeed, the repertoire of EVs that are secreted in complex systems, such as tumors or normal tissues, is expected to greatly exceed that of cultured cells. For example, we found that although the relative abundance of cancer cells and macrophages was similar in MC38 tumors, the large majority (60%) of EVs were TAM-derived. This suggests that TAMs may produce amounts of EVs that could influence the biology of other cell types of the TME, including cancer cells and T cells, either through membrane contacts or upon EV fusion and transfer of functional molecules.

In this study, we performed comparative analysis of the proteomes of EVs secreted from MC38 colorectal tumors treated with either an irrelevant antibody (IgG-EVs) or the macrophage-depleting antibody 2G2 (anti-CSF1R-EVs). By comparing datasets, we compiled a list of TAM EV-associated proteins, which was further refined by implementing an IP strategy based on positive selection of CD11b^+^-myeloid-cell-derived EVs. The resulting dataset identified a TAM-EV signature of 62 proteins, many of which were undetected in EVs from cultured macrophages. Of note, more than one-third of the MC38 TAM-EV-signature proteins were also detected in TAM-EVs isolated from E0771 mammary carcinomas.

Proteins associated with the ER compartment, such as CANX and GP96, are generally regarded as contaminants of EV preparations. We detected ER proteins in tumor-derived EV preparations also after sucrose gradient fractionation, which should separate bona fide EVs (1.14 g/ml mean density) and ER vesicles (1.20 g/ml mean density), as well as after direct IP of CD9^+^ EVs. In agreement with findings of [@bib76], we detected ER-associated proteins in tumor-derived EVs also using a protocol based on enzymatic tissue digestion. Interestingly, ER proteins were not detected in brain-derived EVs after the same enzymatic procedure ([@bib85]), suggesting that the EV repertoire in the TME is likely different from that of neuronal tissues. Although MC38 tumors contain small proportions of non-viable cells, it is possible that tumor-derived EVs also encompass small apoptotic bodies and other membrane vesicles derived from late endosomes or ER. Several studies have described contact sites between ER and late endosome membranes ([@bib22], [@bib68]) and the translocation of some ER proteins to the plasma membrane during cell stress and death ([@bib28]). These processes may be exacerbated in the inflammatory TME and may promote the release of EVs carrying proteins originating from various subcellular compartments.

TAMs largely display immunosuppressive functions in mouse cancer models ([@bib20]). Unexpectedly, our findings indicate that TAM-EVs enriched from MC38 tumors, which are largely populated by immunosuppressive (M2-like) TAMs ([@bib32], [@bib58]), display immunostimulatory molecular profiles and biological properties. Indeed, in addition to typical TAM markers, such as MRC1, F4/80, CD11c, and STAB1 ([@bib64]), the TAM-EV signature was enriched in proteins involved in diverse aspects of immunity, cell signaling, cell adhesion, and lipid metabolism. We detected several positive regulators of the immune response, including pattern recognition receptors such as STING and multiple proteins involved in TLR signaling. The TAM-EV signature also contained members of the DOCK ("dedicator of cytokinesis") family, which are guanine nucleotide exchange factors involved in intracellular signaling networks, chemotaxis, and immunity ([@bib59]). Interestingly, DOCK2, together with its partner ELMO1, mediates the activation and recruitment of lymphocytes ([@bib33], [@bib77]). Furthermore, ITGA4 and F11R, which are involved in leukocyte adhesion and transmigration in brain tumors ([@bib6], [@bib63]), were also detected in the TAM-EV signature. Interestingly, the TAM-EV signature was more strongly associated with the gene expression profile of immunostimulatory M1-like than immunosuppressive M2-like TAMs ([@bib73]). Also, TAM-EV proteins were associated with a good prognosis in patients with cancer, whereas proteins specifically expressed in the source TAMs associated with neither a good nor bad clinical outcome. Finally, EV preparations enriched in TAM-EVs enhanced T cell proliferation and IFNγ production *ex vivo*, whereas EV preparations obtained from TAM-depleted tumors neither suppressed nor activated T cells. Collectively, these findings suggest that TAM-regulated immunomodulatory circuits in the TME might also involve activatory signals conveyed by secreted EVs. EVs isolated from antigen-presenting cells carry MHC-peptide complexes and TLR ligands that can directly activate CD4^+^ and CD8^+^ T cells ([@bib46], [@bib84]). However, the mechanisms involved in the direct activation of T cells by TAM-EVs require further study.

TAMs produce multiple immunomodulatory lipids, and several proteins involved in lipid metabolism were enriched in TAM-EVs compared to source TAMs. Certain enzymes of the AA pathway (such as COX1, TBXAS1, and some CYP proteins) were found in TAM-EVs, whereas others (including COX2, some PTGEs, and LTA4H) appeared either associated with cancer-cell-derived EVs or other cellular sources in the TME, regardless of the presence of TAMs. Notably, we observed that TAM-EVs contain the machinery required for the production of TXs. This finding suggests that TAM-EV-cargo transfer to tumor-associated cells might regulate the biosynthesis of AA-derived lipid mediators. TAM depletion markedly increased the levels of several protumoral PGs, including PGF~2α~ and PGE~2~, which are mostly produced through COX2 ([@bib87]). Although this increase might be explained by the proportional expansion of PG-producing cancer cells after TAM depletion, our results indicate that TAM-EVs can directly limit the production of some PGs and increase TX secretion by MC38 and E0771 cancer cells *in vitro*. Therefore, TAM-EVs may redirect AA catabolism from a COX2-dependent pathway toward a COX1-dependent pathway to possibly limit the protumoral effects of some PGs. The difficulty to recover pure TAM-EV preparations after IP or FACS has limited functional studies in mice. Nevertheless, the TAM-EV protein signature and lipidomic datasets presented in this work may serve as a springboard for further investigations into the roles of TAM-derived EVs in the TME.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------
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Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for reagents and resources, including proteomic raw data, should be directed to and will be fulfilled by the Lead Contact, Michele De Palma (<michele.depalma@epfl.ch>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

C57BL/6 mice were purchased from Charles River Laboratories and Balb/cByJ mice from The Jackson Laboratory. OT-I C57BL/6-Tg(TcraTcrb)1100Mjb/J ([@bib31]), Wap-*ERBB2* B6.Cg-Tg(Wap-ERBB2)229Wzw/J ([@bib61]), C57BL/6/ROSA^mT/mG^ ([@bib56]) and C57BL/6/LysM.Cre ([@bib13]) transgenic mice were available in the EPFL mouse facility. Homozygous LysM.Cre mice were crossed with ROSA^mT/mG^ mice to obtain LysM.Cre/ROSA^mT/mG^ mice, as previously described ([@bib1]). Pups were genotyped by Transnetyx, as detailed on the company's website (<https://www.transnetyx.com>). All mice employed in this study were maintained in pathogen-free barrier animal facilities in accord with Swiss regulations for the care and use of mice in experimental research. All procedures were performed according to protocols approved by the Veterinary Authorities of the Canton Vaud according to the Swiss Law (licenses VD2916, VD3049 and VD3435).

### Cell lines {#sec4.3.2}

Untransduced MC38 cells (P. Romero, Lausanne, Switzerland), MC38 cells expressing human HER2 ([@bib75]) and E0771 cells (J. Huelsken, Lausanne, Switzerland), all of female C57BL/6 origin, were maintained in Iscove's modified Dulbecco's medium (IMDM, Sigma) supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific), 2 mM L-glutamine (GIBCO) and a combination of 50 units/ml penicillin and 50 μg/ml streptomycin (Life Technologies). Cells were routinely tested and resulted negative for *Mycoplasma*.

### Bone marrow-derived macrophages (BMMs) {#sec4.3.3}

To generate primary BMMs, we obtained BM cells by flushing the long bones of 6-week-old female C57BL/6, C57BL/6/ROSA^mT/mG^ or LysM.Cre/ROSA^mT/mG^ mice, as described previously ([@bib75]). BM cells were plated in Macrophage-SFM medium (Thermo Fisher Scientific) supplemented with penicillin--streptomycin and mouse macrophage colony-stimulating factor (CSF1, 100 ng/ml, Peprotech) to promote macrophage differentiation, and cultured for 14 days. In some experiments, BMMs were polarized toward an M1 or M2 phenotype. M1 polarization was induced in presence of IFNγ (20 ng/ml, Peprotech) and lipopolysaccharide (LPS, 5 ng/ml, Sigma), whereas M2 polarization was induced with IL-4 (40 ng/ml, Peprotech), as described ([@bib55]). BMM polarization was initiated at day 7-9 and terminated at day 14 after cell isolation.

### T cells {#sec4.3.4}

Antigen-primed OT-I CD8^+^ T cells were prepared as described previously ([@bib2]). Briefly, freshly-isolated splenocytes from 6- up to 8- week-old female C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I) mice were incubated for 1h with the OVA~257-264~ SIINFEKL peptide (10 nM, GenScript) in RPMI 1640 medium supplemented with 10% FBS, L-glutamine, penicillin/streptomycin, beta-mercaptoethanol (70 μM, GIBCO), gentamycin (23 μg/ml, Sigma), non-essential amino acids (0.1 mM, Sigma) and sodium pyruvate (1 mM, GIBCO). Cells were then cultured in presence of IL-2 (Peprotech) for 4 days to allow for OT-I cell expansion.

Naive CD8^+^ and CD4^+^ T cells were purified from the spleen of 6- up to 8- week-old female C57BL/6 or BALB/c mice using the EasySep™ CD8^+^ and CD4^+^ T cell isolation kits (STEMCELL), according to the manufacturer's instructions.

### Bone marrow-derived dendritic cells (BMDCs) {#sec4.3.5}

To generate primary BMDCs, we obtained BM cells by flushing the long bones of 6-week-old female C57BL/6 mice, as described previously ([@bib75]). BM cells were cultured for six days in RPMI 1640 medium with 10% FBS, L-glutamine, penicillin/streptomycin and granulocyte-macrophage colony-stimulating factor (GM-CSF, 100 ng/ml, Peprotech), prior to functional assays.

### Subcutaneous tumor models {#sec4.3.6}

MC38 cells (1.2x10^6^) or E0771 cells (1.5x10^6^) were injected subcutaneously in the right flank of 6 to 8-week old mice. Specifically, C57BL/6 received injections of MC38 or E0771 cells, whereas LysM.Cre/ROSA^mT/mG^ mice and Wap-*ERBB2* mice received injections of MC38 cells or HER2^+^ MC38 cells, respectively. Both female and male mice were employed after randomization to the various experimental groups. MC38 and E0771 tumors were grown for 14 and 20 days, respectively. Tumor growth was monitored every 2-3 days and tumor size determined by caliper measurements. Tumor volume was calculated using the formula: tumor volume \[mm^3^\] = (length \[mm\])^2^ × (height \[mm\]) × π / 6.

Method Details {#sec4.4}
--------------

### Treatment of mice carrying subcutaneous tumors {#sec4.4.1}

Mice were treated intraperitoneally (i.p.) with 30 mg/kg of either mouse-hamster chimeric IgG1 anti-mouse CSF1R, clone 2G2 (Roche) ([@bib66]); or a control mouse IgG1 (clone MOPC-21; BioXCell), both dissolved in PBS (Dulbecco's PBS, Bioconcept). Treatments were initiated 4 days after cancer cell inoculation. All mice received two (MC38 model) or three (E0771 model) doses of the drugs, once per week.

### Preparation of tumor-derived cells for flow cytometry {#sec4.4.2}

Before euthanasia, deeply anesthetized mice were perfused with PBS to remove intravascular blood cells. Tumors were then harvested, washed in PBS and minced before digestion with collagenase IV (0.2 mg/ml, Life Technologies), dispase (2 mg/ml, Life Technologies) and DNase I (0.002 mg/ml, Life Technologies) in IMDM medium for 20 min at 37°C. The cell suspensions were filtered using a nylon filtration tissue of 150 μm mesh (Sefar). Red blood cells were lysed using a red blood cell lysis buffer (Sigma). Tumor-derived cells were incubated with PBS containing rat anti-mouse FcγIII/II receptor (CD16/CD32) blocking antibodies (4 μg/ml, BD PharMingen, clone 2.4G2) and a fixable viability dye (LIVEDEAD® Fixable Violet or Red, 1:1000, Thermo Fisher Scientific) for 15 min at 4°C before staining with antibodies.

Tumor-derived cell types were identified using the following combinations of cell markers:TAMs: CD45^+^CD11b^+^Ly6C^low^Ly6G^−^F4/80^+^;Tumor monocytes: CD45^+^CD11b^+^Ly6C^+^Ly6G^−^;Tumor neutrophils: CD45^+^CD11b^+^Ly6G^+^;MC38 cancer cells (from LysM.Cre/ROSA^mT/mG^ mice only): CD45^−^GFP^−^tdTomato^−^.

### Flow cytometry {#sec4.4.3}

After blocking and live-dead staining, tumor-derived and cultured immune cells (BMMs, T cells and BMDCs) were stained with the following antibodies (all diluted 1:100) for 30 min at 4°C: rat anti-CD11b-BV711 (clone M1/70, BioLegend), rat anti-CD11b-PE-Cy7 (clone M1/70, eBioscience), rat anti-CD45-V500 (clone 30-F11, BD Biosciences), rat anti-CD45-PerCP-Cy5.5 (clone 30-F11, eBioscience), rat anti-F4/80-APC-Cy7 (clone BM8, BioLegend), rat anti-F4/80-AF647 (clone BM8, BioLegend), rat anti-Ly6G-BV605 (clone 1A8, BioLegend), rat anti-Ly6C-AF700 (clone HK1.4, BioLegend), CD3-APC (clone 17A2, BioLegend), CD8a-APC/Cy7 (clone 53-6.7, BioLegend), CD4-APC/eFluor780 (clone GK1.5, eBioscience), CD40-PE (clone: 3/23, BD Biosciences), CD86-PerCP-Cy5.5 (clone GL-1, BioLegend), CD80-FITC (clone 16-10A1, BioLegend), MHC II-AF647 (clone M5/114.15.2, BioLegend) and CD11c-PacBlue (clone N418, BioLegend). All samples were analyzed with an Attune NxT apparatus (Life Technologies). Compensation was performed using single-stained OneComp eBeads (Thermo Fisher Scientific).

### Immunofluorescence staining of tumor sections {#sec4.4.4}

After intracardiac perfusion of the mice with PBS, tumors were harvested, extensively washed with PBS and immediately embedded in O.C.T compound (Cryomatrix, Thermo Fisher Scientific) on dry ice with iso-pentane (VWR Chemicals) before storage at −80°C. Tissue sections of 8-10 μm were obtained using Leica cryostat CM1950 (Leica Biosystems). Before staining, sections were fixed in methanol for 20 minutes at −20°C, washed three times with PBS for 5 minutes and incubated with blocking solution (1% BSA, 5% FBS in PBS) for 2h at room temperature. Sections were then incubated overnight at 4°C in 100-200 μL of blocking solution containing fluorophore-conjugated antibodies. After staining, nuclei were labeled with DAPI (1 μg/ml, Sigma) and sections mounted in Dako fluorescence mounting medium, covered with cover glass (Heathrow Scientific) and stored at 4°C. The following antibodies were used (all diluted 1:50): rat anti-F4/80-AF488 (clone BM8, BioLegend), rat anti-MRC1-AF647 (clone C068C2, BioLegend), hamster anti-CD11c-PE (clone HL3, BD Biosciences), rat anti-CD11b-FITC (clone M1/70, BD Biosciences) and rat anti-MHC II-AF647 (clone M5/114.15.2, BioLegend).

### Immunofluorescence staining of cultured cells {#sec4.4.5}

BMMs were seeded on FluoroDish™ cell culture dishes (Fisher Scientific) or on glass coverslips (Electron Microscopy Sciences), both previously coated with 50 μg/ml poly-L-lysine (Sigma), and incubated at 37°C until fully adherent (16-24h). In some experiments, cells were imaged live using a confocal microscope, as described below. Alternatively, the medium was aspirated and the cells washed three times with PBS and fixed with 4% paraformaldehyde for 20 min. Cells were then permeabilized with a solution containing 0.3% Triton X-100 in PBS for 20 min and blocked with 10% goat serum in PBS for 1h at room temperature. The primary antibody RAB7-AF647 (EPR7589, Abcam) was diluted 1:200 in blocking solution and applied overnight at 4°C. Nuclei were labeled with DAPI (1 μg/ml, Sigma) and slides were mounted as described above.

### Acquisition of confocal microscopy images {#sec4.4.6}

We used a Zeiss LSM700 confocal microscope coupled to a high sensitivity Axiocam MRm (B/W) camera. A stage-mounted incubation chamber at 37°C, 5% CO~2~ was used for live cell imaging acquisition. Fluorescent signals from individual fluorophores were acquired sequentially from single optical sections.

### Non-enzymatic isolation of EVs from tumor tissue {#sec4.4.7}

Before euthanasia, deeply anesthetized mice were perfused with PBS to remove intravascular blood cells and EVs. Tumors were then harvested, washed in PBS and minced in PBS containing 2 mM EDTA. Tumors were filtered through a 70 μm cell strainer (Corning) using a syringe plunger and transferred to 50 mL tubes. Typically, we obtained 200 mL of tumor-cell suspension after pooling several MC38 tumors (generally between 5 and 15, each of 0.1-1.0 g) from mice of the same treatment group. E0771 tumors from each mouse were harvested and processed individually.

EVs were isolated from tumor-cell suspensions using sequential ultracentrifugation, as previously described ([@bib12], [@bib36], [@bib81]). Briefly, supernatants were centrifuged at 500 x g for 5 min, 2000 x g for 10 min to remove dead cells and debris, and ultracentrifuged at 10,000 x g for 30 min at 4°C to remove large vesicles. Supernatants were then transferred to new tubes and ultracentrifuged at 110,000 x g for 70 min at 4°C to collect small EVs ([@bib38]). EV pellets were then washed in 35 mL of PBS and ultracentrifuged again at 134,000 x g for 70 min at 4°C. All ultracentrifugation steps were performed using a Beckman ultracentrifuge and a SW32Ti rotor. The resulting EV preparations were resuspended in PBS and either used immediately or stored at −80°C.

Unless stated differently, purified tumor-derived EVs were subject to continuous sucrose gradient fractionation using established procedures ([@bib10], [@bib36]). Briefly, 12 stock solutions with decreasing sucrose concentrations were layered on top of purified EVs (400-1000 μg, in 100 μL PBS) in a total volume of 12 ml, followed by ultracentrifugation at 100,000 x g (acceleration, 7; deceleration, no brake) for 16h at 4°C with a Beckman ultracentrifuge and a SW40Ti rotor. Six fractions (2 mL each) were then collected and transferred to new tubes; the density of each fraction was measured using a refractometer. Each fraction was washed with 33 mL of PBS and ultracentrifuged at 134,000 x g for 70 min at 4°C using a SW32Ti rotor. EVs were finally resuspended in 100-200 μL PBS prior to subsequent analyses.

### Enzymatic isolation of EVs from tumor tissue {#sec4.4.8}

When indicated, in parallel to the EV isolation protocol described above, we adapted a recently described procedure for EV purification from tissue ([@bib76], [@bib85]). Briefly, IgG control- or anti-CSF1R-treated MC38 tumors were minced before digestion with collagenase IV (0.2 mg/ml, Life Technologies), dispase (2 mg/ml, Life Technologies) and DNase I (0.002 mg/ml, Life Technologies) in IMDM medium for 20 min at 37°C. Tumor cell suspensions were then cooled down on ice and protease inhibitors (cOmplete™, Roche) added in a final volume of 35 ml. EVs were then isolated using sequential ultracentrifugation and sucrose gradient fractionation, as described above. The average yield of EVs was 1.1 and 0.2 mg per g of tumor before and after sucrose fractionation, respectively.

### Isolation of EVs from continuous and primary cell cultures {#sec4.4.9}

In most of the experiments, MC38 cells (2.2 x10^7^) were seeded in a CELLine™ bioreactor flask (Argos Technologies) in 15 mL of medium containing 5% EV-depleted FBS, which was obtained by ultracentrifugation of standard FBS at 134,000 x g for 16h at 4°C followed by filtration through a 0.1 μm vacuum filtration bottle. One liter of complete medium was then added to the medium compartment. After 7, 14 and 21 days, the supernatant was collected from the cell compartment for EV isolation and replaced with 15 mL of fresh EV-depleted medium. In a minority of the experiments, MC38 cells or E0771 cells were seeded in 15 cm cell culture dishes in complete medium. When cells were at about 50% confluence, they were moved to medium containing 5% EV-depleted FBS (see above).

BMMs were seeded in 10 cm cell culture dishes in SFM medium as described above. Collection of the cell culture supernatant was done every 2-3 days, starting from 8 and up to 14 days after cell seeding. EVs were isolated from the conditioned medium using sequential ultracentrifugation, as described above, with the exception that purified EVs were not subject to sucrose gradient fractionation.

The average yield of EVs obtained with the bioreactor system was 40-55 μg (determined by BCA, see below) per ml of cell culture medium. The average yield of EVs obtained from MC38 cells, E0771 cells and BMMs seeded in cell culture dishes was 1.1 μg, 1.4 μg and 2.8 μg (by BCA) per ml of supernatant, respectively.

### Quantification of EVs {#sec4.4.10}

EV preparations were analyzed for protein content using the BCA protein assay reagent Kit (Thermo Fisher Scientific). The size and concentration of EVs were determined by NTA using a Nanosight NS300 device (Malvern Instruments, UK), as described previously ([@bib36]). Briefly, we tested different sample dilutions (1:100 to 1:5000, in PBS) whereby particle concentration was within the optimal range of detection (5x10^7^ - 1x10^9^ particles/ml). All camera settings were set at the beginning of the session and kept fixed during all acquisitions in a given experiment: camera level, 7; camera gain, 13; detection threshold, 4. For each sample, three videos of 60 s for at least one EV dilution were taken and analyzed using the NTA software 3.0 with default settings.

### Transmission electron microscopy (TEM) of purified EVs {#sec4.4.11}

Purified EVs (5 μg in 15 μL of PBS) were applied to carbon-coated 400 mesh grids (Electron Microscopy Sciences) for 5 min, washed with PBS and negatively stained with 2% uranyl acetate (Electron Microscopy Sciences) for 30 s, as described previously ([@bib12], [@bib36]). Images were obtained using a transmission electron microscope (Tecnai Spirit, FEI Company).

### Western blotting (WB) {#sec4.4.12}

Cells were lysed in ice-cold RIPA buffer (Sigma) containing Halt™ protease and phosphatase inhibitors (Thermo Fisher Scientific). EVs were used without lysis. Protein concentration was determined with the BCA protein assay reagent Kit (Thermo Fisher Scientific). In most experiments, proteins were denatured at 90°C for 10 min with 4x LDS Sample buffer and 10x Reducing agent (both from Life Technologies). In some experiments (namely for blotting of CD63 and F4/80), protein denaturation was performed in the absence of the 10x Reducing agent. Unless stated otherwise, matched protein amounts for each sample were analyzed in each experiment. Proteins (10 to 20 μg) were separated by 4%--12% (gradient) SDS-PAGE (Life Technologies) and blotted onto PVDF membranes (Amersham Hybond 0.45 μm, GE Healthcare).

In most experiments, membranes were blocked with Odyssey Blocking Buffer (LI-COR Biosciences) for 1h at room temperature, incubated with primary antibodies in blocking solution for 24h at 4°C. Membranes were then incubated with IRDye 800CW and 680RD-conjugated secondary antibodies (LI-COR Biosciences) or streptavidin 800CW and 680RD (LI-COR Biosciences) in blocking solution containing 0.1% Tween 20 and 0.01% SDS for 35 min at room temperature. Blots were then imaged using the LI-COR Odyssey scanner.

In some experiments (WB of CD9 and TBXAS1), membranes were blocked with 5% milk and 0.1% Tween 20 in tris-buffered saline (TBS-T) for 1h at room temperature, incubated with primary antibodies in blocking solution for 24h at 4°C and then with horseradish peroxidase (HRP)-conjugated secondary antibodies (GE Healthcare) for 1h at room temperature. The proteins of interest were visualized using the ECL Western Blotting substrate (Pierce) and a Fusion FX device (Vilber Lourmat).

The following antibodies were used: mouse anti-ACTB (clone AC-15, Sigma), mouse anti-ALIX (clone 3A9, Abd Serotec), rabbit anti-CANX (Abcam, ab22595), mouse anti-CASP9 (clone C9, Cell Signaling), rat biotin anti-CD9 (clone KMC8, BD Biosciences), rat anti-CD63 (clone R5G2, MBL), rat anti-CD68 (clone FA-11, GeneTex), mouse anti-CD81 (clone B-11, Santa Cruz), mouse anti-COX1 (clone 5F6/F4, Abcam), rat biotin anti-F4/80 (clone BM8, Biolegend), rabbit anti-GAPDH (clone 16C10, Cell Signaling), rabbit anti-GFP (Thermo Fisher Scientific, A11122), rat anti-GP96 (clone 9G10, Enzo), mouse biotin anti-HER2 (clone e2-4001, Thermo Fisher Scientific), goat anti-MRC1 (R&D, AF2535), rabbit anti-PARP9 (Cell Signaling, 9542), rabbit anti-Syntenin-1 (Invitrogen, PA5-28826,), rabbit anti-STING (clone D2P2F, Cell Signaling), rabbit anti-TBXAS1 (clone EPR7333(2), Abcam), rabbit anti-TBXAS1 (Abcam, ab187176), mouse anti-TSG101 (clone 4A10, Abcam) and rabbit anti-VINCULIN (clone EPR8185, Abcam).

All primary antibodies were used at 1:1000 dilution (except for goat anti-MRC1, mouse anti-TSG101 and rabbit anti-TBXAS1, which were used at 1:500). HRP-conjugated secondary antibodies (GE Healthcare) were incubated at 1:3000 to 1:6000 dilution in TBS-T containing 5% milk for 1h at room temperature. LI-COR secondary antibodies and streptavidins were diluted in Odyssey Blocking Buffer with 0.1% Tween 20 and 0.01% SDS at 1:15,000 and 1:2000, respectively, and incubated for 30 min at room temperature.

### miRNA profiling {#sec4.4.13}

Total RNA was extracted from MC38 tumor-derived EVs (10 μg in 20 μl of PBS) by using the miRNeasy Mini kit (QIAGEN), according to the manufacturer's instructions. RNA was quantified using NanoDrop 2000 (Thermo Fisher Scientific). Reverse transcription (RT) and individual miRNA profiling were performed using TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific), TaqMan Universal PCR Master Mix (Thermo Fisher Scientific) and the following miR TaqMan Assays (Thermo Fisher Scientific): U6, Assay ID: 001973; miR-16-5p, Assay ID: 000391; miR-511-3p, Assay ID: 463069_mat; let-7a-5p, Assay ID: 000377; miR-21, Assay ID: 00397. TaqMan reactions were run for 40 cycles in standard mode using an ABI7900HT apparatus (Applied Biosystems).

### Labeling EVs with fluorescent membrane dyes {#sec4.4.14}

EV labeling with the near IR fluorescent, lipophilic carbocyanine DiOC~18~(7) (DiR) was performed by modifying the manufacturer's protocol (Thermo Fisher Scientific). Briefly, EVs were diluted in PBS prior to addition of the dye (5 μM as final concentration). Labeling was performed for 15 min at room temperature in the dark and terminated using 0.1% BSA (Sigma) in PBS. EVs were loaded onto Vivaspin® 500 columns (300,000 MW cutoff, Sartorius) and centrifuged three times at 4000 x g for 20 min in 0.1% BSA in PBS to retain EVs and discharge free dye/s. Concentrated EVs were resuspended in PBS prior to use.

EV labeling with PKH67 and PKH26 was performed by modifying the manufacturer's protocol (Sigma). Briefly, the EV preparations were diluted in diluent C prior to addition of the dye (1 μl per 100 μl of solution). Labeling was performed for 10 min at room temperature in the dark and terminated using 0.1% BSA (Sigma) in PBS. EVs were washed using Vivaspin® 500 columns (300,000 MW cutoff, Sartorius) as described above.

### Flow cytometry analysis of EVs {#sec4.4.15}

In most of the experiments, EVs were labeled with the fluorescent membrane dye DiR or PKH67 (see above) to distinguish EVs from background noise. MC38-EVs were blocked with rat anti-mouse FcγIII/II receptor (CD16/CD32) blocking antibodies (2 μg/ml) for 15 min at 4°C and stained with mouse anti-HER2-AF647 (1:50, clone 24D2, BioLegend) for 1h at 4°C. Between each step, EVs were washed using Vivaspin® 500 columns (300,000 MW cutoff, Sartorius), as described above.

EV samples were typically diluted in PBS at 50-100 μg/ml, and analyzed using an Attune NxT apparatus (Life Technologies). Acquisition settings were optimized for detection of EV populations carrying green, red or near-infrared fluorescence, or a combination thereof. The conventional blue side scatter (SSC, 488 nm) was replaced by the violet side scatter (vSSC, 405 nm) and the acquisition threshold was set at 0.2 on the vSSC. EVs were gated based on their positivity for DiR and vSSC properties. Compensation was performed using single-stained OneComp eBeads (Thermo Fisher Scientific).

### EV sorting by fluorescence-activated cell sorting (FACS) {#sec4.4.16}

IgG-EVs isolated from MC38 tumors of LysM.Cre/ROSA^mT/mG^ mice were stained with DiR as described above and then diluted in PBS at 30 μg/ml. FACS was performed using a 4-laser MoFlo ASTRIOS EQ cell sorter (Beckman Coulter). EVs were first gated based on DiR fluorescence and side scatter (SSC) properties and then subdivided according to GFP signal. The 488 nm laser was used to assess the SSC and GFP fluorescence (526/52). The 640 nm laser combined with a 795/70 band pass filter was instead used to measure DiR fluorescence. To maximize the amount of collected light, no beam splitter or FSC masks were used. After 6h of continuous sorting, 1x10^6^ GFP^+^/tdTomato^--^ and GFP^--^/tdTomato^--^ EVs were obtained, transferred to polypropylene ultracentrifuge tubes (Beckman) and precipitated by adding four times the sample volume of cold (−20°C) acetone. Samples were incubated for 1h at −20°C prior to centrifugation at 15,000 x g for 15 min. After removing the supernatant, acetone was allowed to evaporate for 30 min at room temperature. Pellets were finally resuspended in 4x LDS Sample buffer and 10x Reducing agent (both from Life Technologies) and denatured at 90°C for 10 min, prior to LC-MS/MS analysis, as described below.

### Immunoprecipitation (IP) of EVs {#sec4.4.17}

IP of EVs was performed using the Exosome-Streptavidin Isolation kit with minor modifications to the manufacturer's instructions (Thermo Fisher Scientific). Briefly, biotinylated antibodies were conjugated to magnetic beads for 1h at room temperature. Meanwhile, 25 μg of EVs were blocked for 30 min at 4°C in a PBS solution containing 0.1% BSA and rat anti-mouse FcγIII/II receptor (CD16/CD32) blocking antibodies (2 μg/ml). EVs were washed twice using Vivaspin® 500 columns (300,000 MW cutoff, Sartorius), as described above. EVs were then incubated with antibody-conjugated beads for 24h at 4°C on a rotating mixer.

Unbound EVs were removed by three consecutive washes using a magnetic separation rack (DynaMag-2, Thermo Fisher Scientific). Immunoprecipitated EVs were denatured at 90°C for 10 min with 4x LDS Sample buffer and 10x Reducing agent (both from Life Technologies) for WB and LC-MS/MS analysis. Alternatively, immunoprecipitated EVs were stained with PKH67 (see above) and washed using the magnetic rack for flow cytometry analysis. The following biotin-conjugated antibodies were used in the IP procedures: rat anti-CD11b (clone M1/70, eBioscience), rat anti-CD9 (clone KMC8, BD PharMingen) and the rat isotype control IgG~2~ (clone RTK2758, BioLegend).

### FACS isolation of CD11b^+^ cells from MC38 tumors {#sec4.4.18}

Cells were obtained from harvested tumors as described above, and stained with LIVEDEAD® Fixable Violet and rat anti-CD11b-BV711 (clone M1/70, BioLegend), rat anti-F4/80-AF488 (clone BM8, BioLegend) and rat anti-CD45-PerCP-Cy5.5 (clone 30-F11, eBioscience) antibodies. CD45^+^CD11b^+^ cells were sorted using a 5-laser FACSAria Fusion SORP cell sorter (Becton Dickinson). FSC, SSC and CD45 (695/40) fluorescence were assessed using the 488 nm laser, whereas LD (450/50) and CD11b (710/50) fluorescence were measured with the 405 nm laser. All gates were set based on Fluorescence Minus One (FMO) controls and the temperature was kept at 4°C throughout the entire process.

### Cell lysate preparation {#sec4.4.19}

Tumor-derived cells and cultured cells were washed in PBS and centrifuged at 500 x g for 5 min. Cell pellets were resuspended in ice-cold RIPA lysis buffer (Sigma) containing Halt™ protease and phosphatase inhibitors (Thermo Fisher Scientific) and incubated for 30 min at 4°C. FACS-sorted CD11b^+^ cells were lysed in PBS containing 2% SDS for 30 min at 4°C. Cell homogenates were centrifuged at 13,000 x g for 20 min and recovered supernatants were stored at −20°C.

### Proteomic analysis by liquid chromatography-mass spectrometry (LC-MS/MS) {#sec4.4.20}

EVs (10 μg, in PBS solution) and cell lysates (10 μg, obtained as described above) were analyzed by LC-MS/MS, as previously described ([@bib11], [@bib12], [@bib36]). EVs obtained after sorting or immunoprecipitation were first resolved on a denaturing 4%--12% polyacrylamide gradient gel (Life Technologies) for a short (10 min at 150V) SDS-PAGE separation; proteins were directly eluted from gels. All samples were then digested in solution and peptides desalted using StageTips, dried in a vacuum concentrator and separated by reverse phase chromatography using a Dionex Ultimate 3000 RSLC nano UPLC system connected in-line with an Orbitrap Elite (Thermo Fisher Scientific).

For analysis, a database search was performed using Mascot 2.5 (Matrix Science) and SEQUEST in Proteome Discoverer v.1.4. against a murine Uniprot protein database. Data were further processed and inspected in Scaffold™ 4.8.7 (Proteome Software), as described below.

### T cell proliferation and activation assays {#sec4.4.21}

Antigen-primed OT-I CD8+ T cells (see "T cells" section above) were labeled with the CellTrace Violet Cell Proliferation Kit, according to the to manufacturer's instructions. Cells were then plated in U-bottom 96-well plates (Corning) at 5x10^5^ cells/ml in T cell medium prepared as described above, with the exception that no IL-2 was supplemented and 5% EV-depleted FBS was used instead of standard FBS. Control PBS or MC38-tumor-EVs (12.5 and 25 μg/ml) were then incubated with the cells for a total of 48h.

Naive CD8^+^ and CD4^+^ T cells from C57BL/6 mice were labeled with the CellTrace Violet (see above) and then incubated for 72h with MC38 tumor-EVs (25 μg/ml) or PBS in EV-depleted medium together with Mouse T-Activator CD3/CD28 Dynabeads (Thermo Fisher Scientific) at a 1:10 ratio (bead:T cell). Similarly, naive CD8^+^ were incubated for 48h with control DMSO or increasing concentrations of PGE~2~ and PGF~2α~ (both from Cayman Chemical) together with CD3/CD28 Dynabeads at a 1:5 ratio (bead:T cell). In the allogenic assay, no CD3/CD28 Dynabeads were used, and CellTrace-labeled naive CD4^+^ T cells from BALB/c mice were incubated solely with MC38 tumor-EVs (25 μg/ml) or PBS for 24h-48h.

T cell proliferation was assessed by flow cytometry analysis, whereas IFNγ secretion in conditioned media was measured with the IFNγ mouse ELISA kit (Thermo Fisher Scientific).

### BMDC assays {#sec4.4.22}

BMDCs were plated in U-bottom 96-well plates at 5x10^5^ cells/ml in BMDC medium prepared as described above, with the exception that 5% EV-depleted FBS was used instead of standard FBS. MC38 tumor-EVs (25 μg/ml) or PBS were then added. Expression of activation markers was assessed by flow cytometry after 24h.

### Analysis of EV-treated cancer cells {#sec4.4.23}

Cancer cells were seeded on poly-L-lysine-coated glass chamber slides (Lab-Tek) or in 48- or 96-well plates (Corning) at a concentration of about 1x10^5^ cells/ml. Cells were incubated with unlabeled or PKH67-labeled tumor-derived EVs for 24h in EV-depleted medium. After incubation with the EVs, cells were washed with PBS and either fixed for immunofluorescence analysis or harvested for WB and flow cytometry analyses.

### Analysis of media conditioned by EV-treated cancer cells {#sec4.4.24}

Cancer cells were seeded in 48- or 96-well plates (Corning) at a concentration of about 1x10^5^ cells/ml. Cells were incubated with tumor-derived EVs for 24h in EV-depleted medium. After incubation with the EVs, cells were washed with PBS and incubated with EV-depleted medium containing the calcium ionophore A23187 (2 μM, Sigma) for 20 min at 37°C. Conditioned media were collected and snap-frozen in liquid nitrogen prior to ELISA and LC-MS/MS lipidomic analysis.

### ELISA {#sec4.4.25}

The concentration of PGE~2~ and TXB~2~ in media conditioned by EV-treated cancer cells was analyzed by ELISA (Enzo) according to the manufacturer's instructions. Absorbance was measured using a TECAN Safire2 plate-reader.

### Analysis of eicosanoid and other oxylipins by LC-MS/MS {#sec4.4.26}

Tumor-derived EVs (100 μg in 45 μL of PBS) and conditioned media (490 μL) were spiked with 10 μL of internal standard (IS) solution and extracted with 200 μL and 500 μL of extraction buffer solution (Na~2~HPO~4~: citric acid, pH 5.6), respectively ([@bib37]). Sample extracts were then loaded onto the Solid Phase Extraction (SPE) cartridge (Oasis HLB 60 mg 96-well Plate, Waters) previously conditioned with methanol and water. Loaded samples were then washed with water/methanol (90:10, v/v) and eluted with methanol (2x750 μL). The eicosanoid extracts were further evaporated to dryness using N~2~ gas (Turbo Vap LV, Biotage) and reconstituted in 60 μL of methanol prior to injection into the LC-MS/MS system.

Snap-frozen MC38 tumors (∼100 mg) were transferred to lysis tubes with ceramic beads (tissue homogenization CK 14 tubes). Samples were homogenized and extracted with 1 mL of ice-cold methanol:water (4:1, v/v) in the Cryolys Percellys homogenizer (5 × 10 s at 10000 rpm, Bertin Technologies). The bead beater was air-cooled at a flow rate of 110 L/min at 10 bar. Homogenized tissue lysates were centrifuged (15 min, 4000 x g at 4°C) and the supernatants (lipid extracts) were evaporated to dryness in a SpeedVac (Labconco) at constant temperature (20°C, CentriVap Cold Trap). The dry extracts were reconstituted by the addition of 90 μl of methanol, 10 μL of IS solution and 900 μl of extraction buffer and subject to SPE, as described above.

Eicosanoid analysis was performed by ultra high performance LC-MS/MS in negative ionization mode using a 1290 UHPLC system coupled to a 6495 triple quadrupole instrument (Agilent). Chromatographic separation was carried out using the Acquity UPLC BEH C18 (1.7 μm, 2.1 mm ID x 150 mm) column (Waters). Mobile phase was composed of 0.1% acetic acid in water (solvent A) and ACN/2-propanol (9:1, v/v) (solvent B) at a flow rate of 0.5 mL/min at 60°C using a gradient elution as described by [@bib37]. Dynamic multiple reaction monitoring (DMRM) was used to acquire the data with a total cycle time of 600 ms. Raw LC-MS/MS data were processed using MassHunter (version B.07.00, Agilent). Absolute quantification was performed using standard calibration curves and stable isotope-labeled internal standards. Relative quantification of eicosanoids was based on the areas of extracted ion chromatograms (EICs). Concentration of specific metabolites was calculated as the ratio between the analyte and the internal standard. For analytes for which the standards were not available, relative quantification was performed using the peak areas of extracted ion chromatograms (EICs).

### Lipidome analysis by reversed phase liquid chromatography coupled to high-resolution mass spectrometry (RPLC-HRMS) {#sec4.4.27}

Tumor-derived EVs (100 μg in 45 μL of PBS) were extracted with ice-cold methanol (200 μL). Samples were vortexed for 20 s and centrifuged at 15,000 x g for 10 min at 4°C. An aliquot of supernatant was transferred to an injection vial for the analysis by RPLC-HRMS. The analysis was carried out in a 1290 Infinity II ultra high-performance liquid chromatography (UHPLC) system coupled to a 6550 iFunnel quadrupole-time-of-flight (Q-TOF) mass spectrometer equipped with a dual AJS electrospray ionization source (Agilent) operating in both positive and negative mode. Lipids were separated on a RP Zorbax Eclipse Plus C18, RRHD (Agilent) (100 mm × 2.1 mm, 1.8 μm particle size) column coupled to a guard column (5 mm × 2 mm, 1.8 μm particle size). Analysis in both positive and negative mode was performed using water with 0.1% formic acid (solvent A) and 2-propanol: acetonitrile (90:10, v/v) with 0.1% formic acid (solvent B). The gradient elution was set as follows: isocratic step of 5% B for 3 min, 5% to 30% B in 2 min, then B was increased to 98% in 13.5 min, maintained at 98% B for 1.5 min, and returned to initial conditions over 0.5 min, then held for a further 4.5 min for column re-equilibration. The flow rate was 0.4 ml/min, injection volume was 2 μL, and the column oven was maintained at 50°C.

The acquisition was done in AIF mode with a mass range of 50-1200 *m/z*, where a single full scan high-resolution data was acquired in three sequential experiments at three alternating collision energies (one full-scan at 0 eV, followed by one MS/MS scan at 10 eV and then followed by one MS/MS scan at 30 eV). The data acquisition rate was 6 scans/s ([@bib57]). Raw LC-HRMS files were processed using the MassHunter Profinder software (Agilent). The relative quantification of lipids was based on EIC (Extracted Ion Chromatograms) areas at the MS level. Lipid identification was performed by AMRT (accurate mass retention time) matching against an in-house database containing several hundreds of lipids using the MassHunter PCDL software (Agilent).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Image processing {#sec4.5.1}

Confocal microscopy images and WB images were analyzed and quantified using FIJI ImageJ.

### TaqMan analysis of miRNAs {#sec4.5.2}

The SDS 2.4 software was used to extract gene expression raw data (Ct). To determine gene expression of miRs, we calculated the difference (ΔCt) between the threshold cycle (Ct) of each gene and that of the reference gene (miR-16-5p). The lower the ΔCt, the higher the gene expression level. Gene expression results are indicated as relative copies calculated with the 2^-ΔCT^ method. Ct values were normalized as indicated in the figure legends.

### Analysis of LC-MS/MS proteomic data {#sec4.5.3}

All peptide/protein data were processed using the Scaffold 4.8.7 (Proteome Software). False discovery rate (FDR) calculation was set to 1% at both peptide and protein levels for the whole study. A protein was considered present if identified by at least three distinct peptides, with the exception of the CD11b IP experiment, in which we used a threshold of at least two peptides. To compare the proteomic profiles of EVs, quantitative values (normalized to total spectra) were used in all experiments, with the exception of the CD11b IP experiment, in which exclusive spectrum counts were used instead.

Proteins enriched in IgG-EVs versus anti-CSF1R-EVs from MC38 tumors were positively selected according to the following criteria: i) detection in all IgG-EV preparations; ii) fold-change abundance \> 1.5 within each experiment; iii) mean fold-change abundance among all experiments \> 1.7. Reciprocally, proteins enriched in anti-CSF1R-EVs versus IgG-EVs were selected based on: i) detection in all anti-CSF1R-EV preparations; ii) fold-change abundance \> 1.5 within each experiment; iii) mean fold-change abundance among all experiments \> 1.7.

Proteins enriched in IgG-Cells versus anti-CSF1R-Cells from MC38 tumors were positively selected according to the following criteria: i) detection in all preparations of FACS-sorted CD11b^+^ cells from IgG-treated tumors; ii) mean fold-change abundance versus FACS-sorted CD11b^+^ cells from anti-CSF1R-treated tumors \> 1.7.

Proteins of MC38-EVs and BMM-EVs were positively selected only if detected in all tested EV preparations.

Proteins of CD11b-immunoprecipiated MC38 IgG-EVs were positively selected if their fold-change abundance versus isotype control-immunoprecipitated IgG-EVs was \> 2. Because IP data were generated from only one IgG-EV preparation, we employed a stricter threshold (FC \> 2) in the IP experiment compared to the differential analyses of IgG-EVs versus anti-CSF1R-EVs (see above). In addition, proteins that were recovered nonspecifically in numerous IP experiments (namely in at least 10% of all the experiments reported in the CRAPome database) were excluded from the final list ([@bib38], [@bib53]).

Proteins enriched in IgG-EVs versus anti-CSF1R-EVs from E0771 tumors were positively selected according to the following criteria: i) detection in all IgG-EV preparations; ii) mean fold-change abundance versus anti-CSF1R-EVs \> 1.7.

### Bioinformatics analysis {#sec4.5.4}

Over-representation analysis of Gene Ontology (GO) terms was performed using the hypergeometric test as implemented in the Molecular Signature Database (MSigDB) web tool ([@bib44]). Immune cell type specificity of genes encoding for candidate proteins was assessed using Immuno-Navigator database ([@bib83]). In brief, mouse gene expression data was obtained from the Immuno-Navigator database, summarized per cell type using median expression, and visualized using the pheatmap R package (see Pheatmap: Pretty Heatmaps. R package version 1.0.10), Pheatmap: Pretty Heatmaps. R package version 1.0.10. <https://cran.r-project.org/web/packages/pheatmap/index.html>) with clustering distance and method set to Euclidean and ward.D2, respectively. Protein-protein interaction (PPI) network including both direct (physical) and indirect (functional) interaction of candidate proteins was generated using String database web tool ([@bib80]).

The radial table of the TAM-EV signature was generated using Circos Table Viewer software (v0.63-9) ([@bib39]).

Enrichment of genes encoding for candidate proteins in sorted TAMs was performed using publicly available data (GEO repository, accession number [GSE34903](ncbi-geo:GSE34903){#intref0390}) from [@bib73] and gene set enrichment analysis (GSEA) ([@bib79]). In brief, matrix of gene-by-sample raw counts was obtained from ARCHS4 database ([@bib40]) and count data were normalized using the cpm functionality within edgeR Bioconductor package ([@bib67]). Consequently, GSEA was performed using fgsea Bioconductor package ([@bib72]), with signal to noise statistic defined in ([@bib79]) as gene ranking criterion.

To assess the association of genes encoding for candidate proteins with prognosis across human cancers, meta-z values summarizing the extent and directionality of association between gene expression and clinical outcome were obtained from the PRECOG database ([@bib29]). Enrichment analysis was performed using the fgsea Bioconductor package ([@bib72]), with meta-z values as gene ranking criterion.

### Statistical analysis and reproducibility {#sec4.5.5}

Information on the study outline, sample size and statistical analysis is presented in the main text, figures, and figure legends. Each study involving tumor-bearing mice was designed to use the minimum number of animals required to obtain sufficient material for further studies (i.e., EV isolation and quantitative data suited to statistical analysis). In the MC38 tumor model, multiple tumors were pooled together from the same experimental cohort before EV isolation; in the E0771 tumor model, each EV preparation was obtained from one tumor.

The investigators were not blinded when assessing the results or analyzing data. Outliers at end-point were not excluded. No specific statistical tests were used to predetermine the sample size. The number of biological replicates for each experiment is indicated in the figure legends; statistics were only computed on independent, non-technical replicates. Multiple EV preparations were obtained and assayed in independent experiments. All functional assays involving EVs and cultured cells were repeated at least in two independent experiments, each containing at least three biological replicates. However, representative samples are often shown in the figures; additional experiments can be requested from the corresponding authors.

Statistical analysis was performed using GraphPad Prism software. Data are shown as mean values ± standard error of the mean (s.e.m.) for most of the analyses, with the exception of experiments with a sample size n = 3, in which mean values ± standard deviation (s.d.) are reported. Statistics were not derived for experiments in which the sample size was \< 3.

Statistical analysis of experiments that involved more than two experimental groups was conducted using one-way ANOVA with Tukey's or Dunnett's correction for multiple comparisons. When the influence of two nominal variables on one measurement variable was examined, a two-way ANOVA followed by Sidak's, Dunnett's or Tukey's correction was used in most of the experiments; Holm-Sidak's correction was used only in the analysis of pre-selected differentially-abundant EV proteins. When specified, in some analyses of lipid MS data, multiple t tests using Holm-Sidak's multiple comparison correction were used to compare multiple variables between two groups. Experiments with a single variable measured in two groups were analyzed with unpaired two-tailed Student's t test with 95% confidence interval.

Statistical significance of the data is indicated as follows: ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001.

Data and Software Availability {#sec4.6}
------------------------------

We have submitted all relevant EV data to the EV-TRACK knowledgebase ([@bib25]), available with EV-TRACK ID: EV190011. Uncropped western blots are available as Mendeley Dataset with [https://doi.org/10.17632/zj43mmthr8.1](10.17632/zj43mmthr8.1){#intref0395}. Processed proteomic data are shown in [Tables S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, [S3](#mmc4){ref-type="supplementary-material"}, [S4](#mmc5){ref-type="supplementary-material"}, [S5](#mmc6){ref-type="supplementary-material"}, [S6](#mmc7){ref-type="supplementary-material"}, and [S7](#mmc8){ref-type="supplementary-material"}. Proteomic raw data are available from the Lead Contact upon request.
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